home · filing · 0001437749-24-026060
8-K filed August 12, 2024, 7:59 PM ET
ticker PLSE
CIK 0001625101
other material
confidence high
sentiment positive
materiality 0.70
Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman
PULSE BIOSCIENCES, INC.
GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.
Oversubscribed rights offering generated $60M gross proceeds; warrants could add up to $66M.
Completed first US soft tissue ablation procedure after FDA clearance; pivotal trial for benign thyroid nodules planned in 2025.
Received FDA Breakthrough Device Designation for Cardiac Surgery System for AF; first European epicardial ablations completed.
Appointed Paul LaViolette as Co-Chairman of Board; he brings 40 years medtech experience from Boston Scientific.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-08-09
Filed August 12, 2024, 7:59 PM ET
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
Effective 2024-08-09
Filed August 12, 2024, 7:59 PM ET
the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors
Effective 2024-08-09
Filed August 12, 2024, 7:59 PM ET
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert W. Duggan was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
Action appointed
Role Co-Chairman of the Board
Exact text from the filing
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul A. LaViolette was elected as Director at PULSE BIOSCIENCES, INC..
Action elected
Role Director
Exact text from the filing
the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul A. LaViolette was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
Action appointed
Role Co-Chairman of the Board
Exact text from the filing
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
View on SEC.gov
Source: SEC EDGAR
accession 0001437749-24-026060
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.